DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on May 2, 2019, by DBV Technologies S.A., a clinical-stage biopharmaceutical company, reports on upcoming investor conference presentations. The company is headquartered in Montrouge, France, and New York, NY, and develops Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform for food allergies and other immune diseases.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a press release regarding corporate events and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses solely on the scheduling of management presentations.
Guidance, Outlook, and Management Commentary
Management has scheduled presentations to discuss the company's progress at two major investor conferences in May 2019:
- Bank of America Merrill Lynch 2019 Health Care Conference: Las Vegas, NV, on May 14, 2019. Presenters include CEO Daniel Tassé and Chief Commercial Officer Kevin Trapp. A live webcast and replay will be available on the company website.
- Barclays West Coast Biopharma Conference: Calistoga, CA, on May 30, 2019. Presenter is Chief Commercial Officer Kevin Trapp.
The company continues ongoing clinical trials for Viaskin Peanut and Viaskin Milk, preclinical development of Viaskin Egg, and a human proof-of-concept study for Viaskin Milk in treating Eosinophilic Esophagitis.
Key Facts for Investor Verification
- Verify the dates and times of the upcoming investor conference presentations (May 14 and May 30, 2019).
- Confirm the availability of the live webcast and replay for the Bank of America Merrill Lynch conference on the company's investor relations website.
- Note that this filing contains no financial data; investors should refer to the most recent Form 20-F or quarterly reports for financial metrics.
- Review the status of clinical trials for Viaskin Peanut, Viaskin Milk, and Viaskin Egg in subsequent regulatory filings.